Dr. Liu jun of TOT BIOPHARM was awarded "high-level talents of jinji lake talent program"
On December 20, at the 2018 suzhou industrial park innovation and development conference and jin-ji lake talent recognition conference, Dr. Liu jun, deputy general manager of TOT BIOPHARM was awarded "jin-ji lake talent program high-level talent". Li yaping, deputy secretary and mayor of suzhou; lu xin, member of the standing committee of the CPC and minister of the organization department of the CPC; wu qingwen, member of the standing committee of the CPC and secretary of the party working committee of the industrial park; lu chunyun, deputy mayor of the municipal government; zhou wei, secretary general of the municipal government attended the meeting, which was presided over by ding lixin, deputy secretary of the party working committee of the industrial park and director of the management committee.
"Jinji lake talent plan" of suzhou industrial park mainly includes five categories: high-level talents, scientific and technological leading talents, scientific and educational talents, etc. It is an important talent plan of suzhou industrial park. In April 2018, suzhou industrial park issued the opinions on deepening the implementation of the "jinji lake talent plan" of suzhou industrial park, deepening the implementation of the "jinji lake talent plan", and building the park into a gathering place for high-level talents. The "jinji lake talents" from each line of the park, a total of 263 people, the Middle East yao pharmaceutical doctor liu jun was awarded the honorary title of "high-level talents" to 33 people. Dr. Liu jun graduated from the university of California, Davis. He has been engaged in the research of biological drugs for nearly 20 years. He has rich experience in the research of new drug development, process development and quality of protein drugs. Dr. Liu jun was awarded as gusu innovation and entrepreneurship leading talent (innovation) in 2017 and jiangsu provincial entrepreneurship and innovation talent (enterprise innovation) in 2018.
The selection, Dr. Liu jun on behalf of the TOT stood out, is the company's scientific research strength and talent competitiveness is a strong embodiment, but also the government at all levels of the company's overall strength of recognition and affirmation. TOT BIOPHARM is committed to the development of high technical barriers and economic value of new drug products, to provide patients with the most appropriate and reasonable price of the product portfolio, to make a positive contribution to the global cancer cause.